|Novel Inhibitors of Thymic Stromal Lymphopoietin (TSLP) for Cancer Therapy|
Description of Invention:
Compositions and methods of using antagonists of thymic stromal lymphopoietin (TSLP) to prevent cancer progression and metastasis.
TSLP, an inflammatory cytokine that is often associated with the induction of allergic responses in the lungs, is also expressed in cancers regulating metastasis. The cancer-promoting activity of TSLP primarily requires signaling through a receptor on CD4+ T-cells, promoting immune responses and production of immunosuppressive factors such as IL-10 and IL-13. Expression of TSLP may be a useful prognostic marker and inhibitors of TSLP could have therapeutic potential. Inactivation of TSLP expression or its receptor signaling was able to effectively diminish cancer progression and metastasis in knock-out mice.
- Treatment to control cancer invasion and spreading while avoiding immune suppression
- Means to augment anti-tumor immune responses
- Development of prognostic markers for disease outcome in cancer patients
- Inactivation of TSLP in knock-out mice was sufficient to diminish both cancer progression and metastasis
- Does not suppress immune system
- In vivo data available (animal)
Bira Arya (NIA)
Warren J Leonard (NHLBI)
- Olkhanud PB, et al. [PMID 21490155]
- De Monte L, et al. [PMID 21339327]
- Pedroza-Gonzalez A, et al. [PMID 21339324]
Collaborative Research Opportunity:
The National Institute on Aging, Immunotherapeutics Unit, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize clinical application of TSLP in cancers. Please contact Nicole Guyton, Ph.D. at 301-435-3101 or firstname.lastname@example.org for more information. Click here to view the NCI collaborative opportunity announcement.
For Licensing Information Please Contact:
Patrick McCue Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
Ref No: 2249